The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...

Scientists at Southern University of Science and Technology in Shenzhen, China, have identified a new regulator of the mammalian target of rapamycin (mTOR) pathway associated with the growth of ...

[31] Deforolimus, a novel mTOR inhibitor, was tested in a group of 55 relapsed/refractory patients with different hematological malignancies (mostly acute leukemia). [32] Interestingly, activity ...